back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2026-03-04 20:34 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Sneddon, Scott
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Notes (US$)
16 - Acquisition or disposition under a prospectus exemption
|
+$25,000 vol |
$25,000 | |
| Filed 2026-03-04 20:29 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Sneddon, Scott
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$25,000 vol |
||
| Filed 2026-03-04 14:55 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Sneddon, Scott
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$25,000 vol |
||
| Filed 2026-03-04 14:55 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Sneddon, Scott
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
+$25,000 vol |
$25,000 | |
| Filed 2026-03-04 14:54 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Sneddon, Scott
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
$
+$25 vol $1,000 each |
||
| Filed 2026-03-04 14:53 Tx date 2026-02-27 |
$SHRX
Sharp Therapeutics Corp. |
Sneddon, Scott
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Notes
16 - Acquisition or disposition under a prospectus exemption
|
$
+$25 vol $1,000 each |
||
| Filed 2026-03-04 14:52 Tx date 2024-12-11 |
$SHRX
Sharp Therapeutics Corp. |
Sneddon, Scott
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Convertible Notes
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2025-09-09 10:26 Tx date 2025-08-25 |
$SHRX
Sharp Therapeutics Corp. |
Sneddon, Scott
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,050
+500 vol $2.10 each |
870,747 | |
| Filed 2025-09-09 10:09 Tx date 2025-08-26 |
$SHRX
Sharp Therapeutics Corp. |
Sneddon, Scott
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$73.22
+100 vol $0.73 each |
870,847 | |
| Filed 2025-02-06 14:26 Tx date 2025-01-27 |
$SHRX
Sharp Therapeutics Corp. |
Sneddon, Scott
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-8,345,648 vol |
927,294 | |
| Filed 2025-02-06 14:24 Tx date 2025-01-27 |
$SHRX
Sharp Therapeutics Corp. |
Sneddon, Scott
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-7,832,223 vol |
870,247 | |
| Filed 2024-12-18 10:06 Tx date 2024-12-11 |
$SHRX
Sharp Therapeutics Corp. |
Sneddon, Scott
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
9,272,942 | ||
| Filed 2024-12-18 10:04 Tx date 2024-12-11 |
$SHRX
Sharp Therapeutics Corp. |
Sneddon, Scott
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
8,702,470 |